TGFβ signaling hyperactivation-induced tumorigenicity during the derivation of neural progenitors from mouse ESCs

Journal of Molecular Cell Biology
Xianfa YangYunbo Qiao

Abstract

Clinical therapies of pluripotent stem cells (PSCs)-based transplantation have been hindered by frequent development of teratomas or tumors in animal models and clinical patients. Therefore, clarifying the mechanism of carcinogenesis in stem cell therapy is of great importance for reducing the risk of tumorigenicity. Here we differentiate Oct4-GFP mouse embryonic stem cells (mESCs) into neural progenitor cells (NPCs) and find that a minority of Oct4+ cells are continuously sustained at Oct4+ state. These cells can be enriched and proliferated in a standard ESC medium. Interestingly, the differentiation potential of these enriched cells is tightly restricted with much higher tumorigenic activity, which are thus defined as differentiation-resistant ESCs (DR-ESCs). Transcriptomic and epigenomic analyses show that DR-ESCs are characterized by primordial germ cell-like gene signatures (Dazl, Rec8, Stra8, Blimp1, etc.) and specific epigenetic patterns distinct from mESCs. Moreover, the DR-ESCs possess germ cell potential to generate Sycp3+ haploid cells and are able to reside in sperm-free spermaduct induced by busulfan. Finally, we find that TGFβ signaling is overactivated in DR-ESCs, and inhibition of TGFβ signaling eliminates the ...Continue Reading

References

Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lars M BjorklundOle Isacson
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jamie M SpergerJames A Thomson
Jul 24, 2004·Nature Medicine·Olle LindvallAlberto Martinez-Serrano
Jul 1, 2006·Nature·Olle Lindvall, Zaal Kokaia
Feb 9, 2007·Nature Biotechnology·Duncan E C BakerPeter W Andrews
Jul 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Fabio CannataCarine Giovannangeli
Sep 2, 2009·Biochemical and Biophysical Research Communications·Hiroyuki IchidaTomoko Abe
Mar 11, 2011·Nature Reviews. Cancer·Uri Ben-David, Nissim Benvenisty
May 5, 2011·Nature Cell Biology·Sean M Wu, Konrad Hochedlinger
Mar 26, 2013·The Journal of Clinical Investigation·Lu CuiYing Jin
Aug 8, 2013·Nature Medicine·Andrew S LeeJoseph C Wu
Jan 18, 2014·Nature Reviews. Genetics·Viviane Tabar, Lorenz Studer
Jul 4, 2015·Cell Stem Cell·Alan Trounson, Courtney McDonald
Feb 5, 2016·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Chao FengFangpu Han

❮ Previous
Next ❯

Citations

Jan 12, 2019·Cell Research·Wenqian SongYi Arial Zeng
Aug 12, 2019·ACS Biomaterials Science & Engineering·Yan-Lei FanXi-Qiao Feng
Nov 4, 2021·Molecular Biology Reports·Sedigheh Momenzadeh, Mohammad-Saeid Jami

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.